{"id":25162,"date":"2026-01-11T00:08:05","date_gmt":"2026-01-10T18:38:05","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&p=25162"},"modified":"2026-01-11T00:08:05","modified_gmt":"2026-01-10T18:38:05","slug":"%e0%a4%a8%e0%a5%88%e0%a4%9f%e0%a4%95%e0%a5%8b-%e0%a4%ab%e0%a4%be%e0%a4%b0%e0%a5%8d%e0%a4%ae%e0%a4%be-%e0%a4%95%e0%a5%88%e0%a4%82%e0%a4%b8%e0%a4%b0-%e0%a4%95%e0%a5%80-%e0%a4%a6%e0%a4%b5%e0%a4%be","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/%e0%a4%a8%e0%a5%88%e0%a4%9f%e0%a4%95%e0%a5%8b-%e0%a4%ab%e0%a4%be%e0%a4%b0%e0%a5%8d%e0%a4%ae%e0%a4%be-%e0%a4%95%e0%a5%88%e0%a4%82%e0%a4%b8%e0%a4%b0-%e0%a4%95%e0%a5%80-%e0%a4%a6%e0%a4%b5%e0%a4%be\/","title":{"rendered":"“\u0928\u0948\u091f\u0915\u094b \u092b\u093e\u0930\u094d\u092e\u093e: \u0915\u0948\u0902\u0938\u0930 \u0915\u0940 \u0926\u0935\u093e, \u0928\u093f\u0935\u0947\u0936\u0915\u094b\u0902 \u0915\u093e \u092d\u0930\u094b\u0938\u093e!”"},"content":{"rendered":"

Natco Pharma (NATCOPHARM) trades deeply oversold \u20b9890 with extreme capitulation signals presenting premier dip-buy opportunity above 200MA \u20b9954-965 support. Technicals RSI 31-39 Sell, STOCHRSI 5-93 Oversold-Overbought extremes, all short-term MAs Sell (10\/2) but weekly momentum bullish targeting \u20b9917-976 resistance; fundamentals showcase oncology leadership with \u20b91,361 intrinsic value vs current \u20b9890 (35% undervaluation).<\/p>\n

Detailed Technical Analysis:
\n<\/strong>Current Price Action: \u20b9890.20 Jan 9 close (-2.13% from \u20b9909.70), weekly +0.23%, monthly -0.79%, YTD mixed. RSI(14) 31.315-39.846 Sell extreme oversold territory, STOCH(9,6) 13.739 Oversold, STOCHRSI(14) 5.764 Oversold, Williams %R -93.67 Oversold, CCI(14) -111.14 Sell all screaming capitulation bounce. MACD(12,26) -14.57 Sell, ADX(14) 39.67 Sell confirms downtrend exhaustion, ATR(14) 11.79 low volatility breakout pending, ROC -6.18 Sell momentum slowing.<\/p>\n

Moving Averages: Short-term bearish MA5 \u20b9971-974 Sell, MA10 \u20b9982 Sell, MA20 \u20b9999 Sell, MA50 \u20b91017 Sell but MA100 \u20b91004 Sell, MA200 \u20b9954-965 Buy providing floor. Pivot Points: \u20b9876.43 pivot holds, R1 \u20b9891.86 (+0.2%), R2 \u20b9902.13 (+1.3%), R3 \u20b9917.56 (+3.1%); S1 \u20b9866.16 (-2.7%), S2 \u20b9850.73 (-4.5%), S3 \u20b9840.46 (-5.6%). Trading Strategy: Accumulate \u20b9870-885 targeting \u20b9910-920 (R2-R3), trailing SL \u20b9850.<\/p>\n

Detailed Fundamental Analysis:
\n<\/strong>Financial Snapshot: Revenue TTM strong oncology generics, PAT healthy, Intrinsic Value \u20b91,361 (Smart-Investing model) vs \u20b9890 = 35% undervaluation. Oncology portfolio Revlimid, Imbruvica, Keytruda biosimilars pipeline, US FDA approvals pipeline. ROE 18.24%, Debt\/Equity comfortable, Cash reserves support R&D\/capex. P\/E attractive vs sector post correction, Dividend yield consistent. Growth drivers: Complex generics leadership, Emerging markets expansion, CDMO pipeline FY26-27.<\/p>\n

Reasons for Recent Downfall:
\n<\/strong>Sequential decline Jan 7 \u20b9930 \u2192 Jan 8 \u20b9909 (-2.3%) \u2192 Jan 9 \u20b9890 (-2.1%) total -4.4% despite broader pharma resilience. Technical breakdown below MA20 \u20b9999 triggered algo selling cascade, high ADX 39.67 confirmed downtrend. Profit booking post \u20b91,419 52W high (Dec 2025), FII selling pharma overweight adjustment, US FDA litigation overhang (Jan 7 clarification no material impact), delivery volume contraction signaled conviction selling.<\/p>\n

Will Rally Continue or More Downside?:
\n<\/strong>Bounce continuation probable post oversold capitulation – STOCHRSI 5.764 + Williams -93.67 extremes rarely sustained beyond 2-3 days. \u20b9876 pivot intact targets \u20b9902-917 immediate. Downside capped \u20b9850 (S2) unless MA200 \u20b9954 decisively breaks risking \u20b9840. Momentum favors 65% upside probability next 5-7 sessions pre-results.<\/p>\n

Micro & Macro View:
\n<\/strong>Micro (1-3 months): Oversold reversal high probability entry \u20b9870-890 targeting \u20b9950-970, catalyst Q3 results + FDA updates. Macro (6-12 months): Bullish specialty pharma 25%+ revenue CAGR, oncology dominance, target \u20b91,300-1,400 (45-55% upside). Tailwinds: US generics pricing stabilization, Biosimilars ramp-up FY27.<\/p>\n

Upcoming News\/Events & Impact:
\n<\/strong>Q3 Results (late Jan): Oncology revenue beat + pipeline updates \u2192 15% rally \u20b91,030+; Margin pressure\/GnRH delay \u2192 \u20b9800 test. US FDA litigation outcome (Jan clarification ongoing), Keytruda biosimilar timeline critical catalysts. FY26 guidance complex generics pipeline size decisive.<\/p>\n

Disclaimer & Disclosure:
\n<\/strong>Educational analysis exclusively – NO investment advice, recommendation, or solicitation. Capital loss risk substantial. Past performance irrelevant. Mandatory SEBI-registered advisor consultation. Investogainer Research disclaim all liability. Public domain data Jan 10, 2026; no positions\/associate holdings.<\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[388,761,386,400,130,183,121,186,169,235,92,116,127,155],"class_list":["post-25162","article","type-article","status-publish","hentry","article-category-learn","article-tags-calloptions","article-tags-nifty-banknifty-optiondata","article-tags-optionstrading","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-investingtips","article-tags-investment-opportunities","article-tags-investmenteducation","article-tags-investmentstrategy","article-tags-nifty50","article-tags-sebi-registered-advisors","article-tags-signalzinvestmenttips","article-tags-successful-investing","article-tags-wealthbuilding"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/25162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=25162"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=25162"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=25162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}